Clinical Trials Logo

Clinical Trial Summary

Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03778502
Study type Observational [Patient Registry]
Source University of Malta
Contact Nicoletta Riva, MD, PhD
Phone +356 2340 1870
Email nicoletta.riva@um.edu.mt
Status Recruiting
Phase
Start date October 1, 2019
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT04569279 - Rivaroxaban vs. Warfarin in CVT Treatment Phase 3
Completed NCT02585713 - Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Phase 3
Active, not recruiting NCT03329365 - Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
Not yet recruiting NCT05211102 - Venous Sinus Thrombosis : Clinical Picture and Outcome
Active, not recruiting NCT03080883 - Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Phase 3
Recruiting NCT05021198 - The Norwegian Cerebral Venous Thrombosis Study
Completed NCT05448248 - Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)